BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Diagnosis
134 results:

  • 1. Lymphangioleiomyomatosis in patients with tuberous sclerosis: a national centre audit.
    Johnson J; Somerfield W; Johnson SR
    Orphanet J Rare Dis; 2024 Mar; 19(1):137. PubMed ID: 38532450
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Glutamine synthetase and hepatocellular carcinoma.
    Jiang J; Hu Y; Fang D; Luo J
    Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102248. PubMed ID: 37979911
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Molecular insight into renal cancer and latest therapeutic approaches to tackle it: an updated review.
    Murali R; Gopalakrishnan AV
    Med Oncol; 2023 Nov; 40(12):355. PubMed ID: 37955787
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. [Genetic diffuse cystic lung disease in adults].
    Diesler R; Ahmad K; Chalabreysse L; Glérant JC; Harzallah I; Touraine R; Si-Mohamed S; Cottin V
    Rev Mal Respir; 2024 Jan; 41(1):69-88. PubMed ID: 37951745
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Identification of a Novel TSC2 c.170G>A Missense Variant: A Case Report and Elaboration on the Yield of Targeted Options against Tuberous Sclerosis Complex Manifestations.
    Papageorgiou G; Skouteris N; Valavanis C; Stanc GM; Souka E; Charalampakis N
    Rev Recent Clin Trials; 2023; 18(4):304-312. PubMed ID: 37877150
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT.
    Ricci C; Ambrosi F; Franceschini T; Giunchi F; Grillini A; Franchini E; Grillini M; Schiavina R; Massari F; Mollica V; Tateo V; Bianchi FM; Bianchi L; Droghetti M; Maloberti T; Tallini G; Colecchia M; Acosta AM; Lobo J; Trpkov K; Fiorentino M; de Biase D
    Virchows Arch; 2023 Nov; 483(5):687-698. PubMed ID: 37845471
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. A Rare Presentation of Aggressive Renal Cell Carcinoma and the Utility of Early Molecular Testing in Rapidly Progressing Malignancies: A Case Report.
    McLoughlin DE; Chevalier N; Choy E; Cote GM; Gao X; Juric D; Reynolds KL
    Oncologist; 2023 Dec; 28(12):1094-1099. PubMed ID: 37844295
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. PLCL1 suppresses tumour progression by regulating AMPK/mtor-mediated autophagy in renal cell carcinoma.
    Pan Z; Huang J; Song H; Xiao Y; Liu T; Zeng Y; Zhu H; Yang K
    Aging (Albany NY); 2023 Oct; 15(19):10407-10427. PubMed ID: 37801481
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Concordance of mtor Pathway Mutations and the diagnosis of Renal Low-Grade Oncocytic Tumor (LOT).
    Siegmund SE; Al-Obaidy KI; Tsai HK; Idrees MT; Akgul M; Acosta AM; Hirsch MS
    Int J Surg Pathol; 2024 Apr; 32(2):316-330. PubMed ID: 37357748
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Macrophage-derived exosomal miR-342-3p promotes the progression of renal cell carcinoma through the NEDD4L/CEP55 axis.
    Feng J; Xu B; Dai C; Wang Y; Xie G; Yang W; Zhang B; Li X; Wang J
    Oncol Res; 2021; 29(5):331-349. PubMed ID: 37305161
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma.
    Lang M; Schmidt LS; Wilson KM; Ricketts CJ; Sourbier C; Vocke CD; Wei D; Crooks DR; Yang Y; Gibbs BK; Zhang X; Klumpp-Thomas C; Chen L; Guha R; Ferrer M; McKnight C; Itkin Z; Wangsa D; Wangsa D; James A; Difilippantonio S; Karim B; Morís F; Ried T; Merino MJ; Srinivasan R; Thomas CJ; Linehan WM
    J Exp Clin Cancer Res; 2023 Apr; 42(1):99. PubMed ID: 37095531
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Reprint of: lessons from histopathologic examination of nephrectomy specimens in patients with tuberous sclerosis complex: cysts, angiomyolipomas & renal cell carcinoma.
    Gupta S; Stanton ML; Reynolds JP; Whaley RD; Herrera-Hernandez L; Jimenez RE; Cheville JC
    Hum Pathol; 2023 Mar; 133():136-152. PubMed ID: 36894367
    [TBL] [Abstract] [Full Text] [Related]  

  • 13.
    Zhang KJ; Qu Z; Pszenica E; Hafron JM; Zhang PL; Brown RE
    Ann Clin Lab Sci; 2023 Jan; 53(1):3-13. PubMed ID: 36889765
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Low-grade oncocytic tumour (LOT) of the kidney is characterised by GATA3 positivity, FOXI1 negativity and mtor pathway mutations.
    Chen T; Peng Y; Lei T; Wu C; Wang H; Shi Y
    Pathol Oncol Res; 2023; 29():1610852. PubMed ID: 36816543
    [No Abstract]    [Full Text] [Related]  

  • 15. TSC/mtor mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases.
    Tjota MY; Sharma A; Wanjari P; Fitzpatrick C; Segal J; Antic T
    Hum Pathol; 2023 Apr; 134():124-133. PubMed ID: 36592877
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. New insights in the new WHO classification of adult renal tumors.
    Hes O; Michalová K; Pivovarčíková K
    Cesk Patol; 2022; 67(4):187-191. PubMed ID: 36513503
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Proteogenomic characterization of MiT family translocation renal cell carcinoma.
    Qu Y; Wu X; Anwaier A; Feng J; Xu W; Pei X; Zhu Y; Liu Y; Bai L; Yang G; Tian X; Su J; Shi GH; Cao DL; Xu F; Wang Y; Gan HL; Ni S; Sun MH; Zhao JY; Zhang H; Ye D; Ding C
    Nat Commun; 2022 Dec; 13(1):7494. PubMed ID: 36470859
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. The roles and mechanisms of circular RNAs related to mtor in cancers.
    Cao C; Wang Y; Wu X; Li Z; Guo J; Sun W
    J Clin Lab Anal; 2022 Dec; 36(12):e24783. PubMed ID: 36426933
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Clinical phenotypes and long-term outcome of kidney involvement in Erdheim-Chester histiocytosis.
    Chazal T; Pegoraro F; Manari G; Bettiol A; Maniscalco V; Gelain E; Charlotte F; Mazor RD; Renard-Penna R; Amoura Z; Cohen-Aubart F; Haroche J; Izzedine H; Vaglio A
    Kidney Int; 2023 Jan; 103(1):177-186. PubMed ID: 36374823
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. LOT and HOT … or not. The proliferation of clinically insignificant and poorly characterised types of renal neoplasia.
    Samaratunga H; Egevad L; Thunders M; Iczskowski KA; van der Kwast T; Kristiansen G; Pan CC; Leite KRM; Evans A; Clouston D; Kenwright DN; Bethwaite PB; Malone G; Wood S; Yaxley JW; Delahunt B
    Pathology; 2022 Dec; 54(7):842-847. PubMed ID: 36270849
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 7.